首页> 外文OA文献 >Prognostic significance of high hyperdiploid and tri-/tetraploid adult acute myeloid leukemia.
【2h】

Prognostic significance of high hyperdiploid and tri-/tetraploid adult acute myeloid leukemia.

机译:高二倍体和三/四倍体成人急性髓性白血病的预后意义。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Purpose To ascertain the clinical implications of high hyperdiploid (HH; 49-65 chromosomes) and tri-/tetraploid (TT; >65 chromosomes) adult acute myeloid leukemia (AML), all such cases were retrieved from the Swedish AML Registry. Results Of the 3,654 cytogenetically informative cases diagnosed between January 1997 and May 2014, 68 (1.9%) were HH (n=50)/TT (n=18). Patients with HH/TT were older than those with intermediate risk (IR) AML (median 71 years versus 67 years; P = 0.042) and less often had de novo AML (63% versus 79%; P = 0.004); no such differences were observed between HH/TT and complex karyotype (CK) AML. The overall survival (OS) was similar between patients with HH/TT and CK AML (median 0.9 years versus 0.6 years; P = 0.082), whereas OS was significantly longer (median 1.6 years; P = 0.028) for IR AML. The OS was shorter for cases with HH than with TT (median 0.6 years versus 1.4 years; P = 0.032) and for HH/TT AMLs with adverse abnormalities (median 0.8 years versus 1.1 years; P = 0.044). Conclusions In conclusion, HH/TT AML is associated with a poor outcome, but chromosome numbers >65 and absence of adverse aberrations seem to translate into a more favorable prognosis. Thus, HH/TT AMLs are clinically heterogeneous and should not automatically be grouped as high risk. This article is protected by copyright. All rights reserved.
机译:目的为了确定高双倍体(HH; 49-65个染色体)和三倍体/四倍体(TT;> 65个染色体)成人急性髓细胞性白血病(AML)的临床意义,所有此类病例均从瑞典AML注册中心检索。结果在1997年1月至2014年5月之间诊断的3,654例细胞遗传学信息病例中,有68例(1.9%)为HH(n = 50)/ TT(n = 18)。患有HH / TT的患者年龄大于患有中等风险(IR)AML的患者(中位年龄为71岁vs 67岁; P = 0.042),而从头进行AML的患者较少(63%vs 79%; P = 0.004);在HH / TT与复杂核型(CK)AML之间未观察到此类差异。患有HH / TT和CK AML的患者的总生存期(OS)相似(中位0.9年vs 0.6年; P = 0.082),而IR AML的OS明显更长(中位1.6年; P = 0.028)。伴有HH的患者的OS短于TT(中位0.6年vs.1.4年; P = 0.032)和伴有不良异常的HH / TT AML(中位0.8年vs.1.1年; P = 0.044)。结论总之,HH / TT AML与不良预后相关,但染色体数> 65和无不良像差似乎可以预示更佳的预后。因此,HH / TT AML在临床上是异质的,不应自动归类为高风险。本文受版权保护。版权所有。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号